Epigenetics Market by End Users, and by Geography North America, Latin America, Europe

Increasing research to study the epigenetics of the genome (study called epigenomics) is expected to boost growth of the epigenetics market over the forecast period. Genome-wide epigenetic studies play an important role in the diagnostics of human diseases. Moreover, implementation of epigenetics for oncology research is estimated to propel the growth of epigenetics market. For instance, Constellation Pharmaceuticals, in April 2018, invested US$ 100 million for development of cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are designed to demonstrate the potential for CPI-1205 and CPI-0610, used for cancer therapy. Moreover, increasing whole genome sequencing projects such as Human Genome Project is resulting into increasing adoption of epigenetic-based products, which in turn is driving growth of the epigenetics market size.

Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1772

Increasing government initiatives to enhance epigenetic research is fueling growth of the epigenetics market. For instance, in 2017, National Institutes of Health (NIH) planned to award 10 grants for supporting social epigenomics research in health disparities. The National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health, committed US$ 26.2 million for nine awards over the term of five year. Moreover, in 2011, epigenetic related research was awarded US$ 11 million grant by the U.S. National Institute of Environmental Health Sciences. In same year, European Commission launched US$ 52.1 million project named BLUEPRINT, which aims to generate 100 reference epigenomes of healthy and leukaemic cells.

Furthermore, organic and inorganic growth strategies such as merger, collaboration, acquisition and product launches by market players of epigenetics market are expected to fuel growth of the epigenetics market. For instance, in 2012, Epizyme partnered with Summit, a subsidiary of Celgene to develop personalized therapeutics for patients with genetically defined cancers by inhibiting histone methyl transferases (HMTs), an important epigenetic target class. Under this agreement, Celgene will receive an exclusive license outside the U.S. to some of Epizyme’s programs for the period of three years and has the right to extend this option period for one year with additional funding. Moreover, In January 2016, Merck collaborated with the Cancer Research Technology in U.K., to develop inhibitors of protein arginine methyltransferase 5 (PRMT5).

Click To Continue Reading
https://www.coherentmarketinsights.com/ongoing-insight/epigenetics-market-1772

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org

This release was published on openPR.